Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AP02

Other · developed by Avalyn Pharma

Phase 2 Most advanced trial
AVLN Developer
1 Registered trials

What is AP02?

AP02 is a drug studied in idiopathic pulmonary fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Avalyn Pharma Inc. (AVLN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07194382 Phase 2 Idiopathic Pulmonary Fibrosis (IPF) Recruiting AVLN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary Fibrosis (IPF)

Follow AVLN, the company behind AP02

See AVLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVLN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.